Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.48 |
| ▸ | MPO | P05164 | 1/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.37 |
| ▸ | PREP | P48147 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | SPR | P35270 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15273089 | 1.00 | NR1H2 (0.48) | NR1H2MPODDB1CRBNJAK1 | |
| SCHEMBL27921574 | 0.93 | NR1H2 (0.44) | NR1H2MPODDB1CRBNJAK1 | |
| SCHEMBL985090 | 0.90 | MPO (0.46) | NR1H2MPODDB1CRBNGPR119 | |
| SCHEMBL12539010 | 0.86 | NR1H2 (0.49) | NR1H2DDB1CRBNJAK1GPR119 | |
| SCHEMBL15270991 | 0.86 | MPO (0.40) | NR1H2MPODDB1CRBNGPR119 | |
| SCHEMBL25710881 | 0.85 | NR1H2 (0.48) | NR1H2DDB1CRBNJAK1GPR119 | |
| SCHEMBL25710889 | 0.85 | NR1H2 (0.48) | NR1H2DDB1CRBNJAK1GPR119 | |
| SCHEMBL15273480 | 0.85 | MPO (0.40) | NR1H2MPODDB1CRBNGPR119 | |
| SCHEMBL16267942 | 0.83 | DDB1 (0.49) | MPODDB1CRBNGPR119USP30 | |
| SCHEMBL26388949 | 0.83 | DDB1 (0.49) | MPODDB1CRBNGPR119USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481524-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-09 | — | — | US | disclosed |
| US-20110136789-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-09 | — | — | US | disclosed |
| EP-2205589-B1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2011-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136789-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | NR1H2 2477/4885MPO 4325/4885DDB1 1210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.